683 Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

683 Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5M	Buy	35,000 +14,000	+67%	+$4.22M	0.52%	46
2026 Q1	$6.95M	Buy	21,000 +17,218	+455%	+$5.86M	0.36%	57
2025 Q4	$1.5M	Buy	+3,782	New	+$1.67M	0.07%	118
2022 Q3	–	Sell	-39,000	Closed	-$5.69M	–	241
2022 Q2	$5.69M	Sell	39,000 -10,000	-20%	-$1.42M	0.4%	68
2022 Q1	$8M	Hold	49,000	–	–	0.43%	61
2021 Q4	$8.31M	Hold	49,000	–	–	0.31%	73
2021 Q3	$9.25M	Sell	49,000 -6,000	-11%	-$1.13M	0.36%	68
2021 Q2	$9.32M	Hold	55,000	–	–	0.32%	67
2021 Q1	$7.76M	Sell	55,000 -50,000	-48%	-$7.52M	0.41%	59
2020 Q4	$13.6M	Hold	105,000	–	–	0.65%	39
2020 Q3	$15.3M	Hold	105,000	–	–	1.12%	21
2020 Q2	$15.6M	Sell	105,000 -65,000	-38%	-$8.76M	1.24%	22
2020 Q1	$18.5M	Sell	170,000 -55,000	-24%	-$6.35M	2.17%	12
2019 Q4	$25.9M	Sell	225,000 -129,000	-36%	-$12.9M	2.96%	7
2019 Q3	$28.5M	Buy	354,000 +14,000	+4%	+$1.11M	3.17%	4
2019 Q2	$24.7M	Buy	340,000 +14,000	+4%	+$1.07M	2.24%	9
2019 Q1	$30.5M	Hold	326,000	–	–	2.76%	7
2018 Q4	$23.8M	Buy	326,000 +26,000	+9%	+$2M	1.44%	13
2018 Q3	$26.3M	Hold	300,000	–	–	1.7%	12
2018 Q2	$29.5M	Buy	300,000 +110,000	+58%	+$10.9M	2%	8
2018 Q1	$22.6M	Sell	190,000 -10,000	-5%	-$1.29M	2%	13
2017 Q4	$25.4M	Sell	200,000 -39,500	-16%	-$4.96M	2.14%	9
2017 Q3	$28.1M	Sell	239,500 -30,500	-11%	-$2.6M	2.96%	7
2017 Q2	$21.5M	Hold	270,000	–	–	3.17%	5
2017 Q1	$13.8M	Hold	270,000	–	–	2.15%	15
2016 Q4	$10.1M	Buy	270,000 +150,000	+125%	+$6.28M	0.72%	36
2016 Q3	$8.13M	Buy	+120,000	New	+$8.47M	0.86%	36

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's ALNY Position: Q2 2026 in Review

683 Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 67% in Q2 2026, buying an estimated $4.22M and bringing the position to 35,000 shares worth $10.5M. The position accounts for 0.52% of the portfolio, ranked #46.

683 Capital Management first reported a position in ALNY in Q3 2016 and has held it in 27 quarters since. The position peaked at $30.5M in Q1 2019. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

683 Capital Management held 35,000 shares of Alnylam Pharmaceuticals worth $10.5M as of Q2 2026.
683 Capital Management bought 14,000 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.22M.
Alnylam Pharmaceuticals made up 0.52% of 683 Capital Management's portfolio in Q2 2026, its #46 holding.
683 Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 27 quarters since.
683 Capital Management's Alnylam Pharmaceuticals position peaked at $30.5M in Q1 2019.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.